$19.50
Value $5.5B
CAI and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$19.50
Value $5.5B
$137.75
Value $341B
Caris Life Sciences (CAI) has a market value of $5.5B and Merck & Company (MRK) $341B. Over the last year, with dividends, CAI moved -17.8% and MRK +52.7%. The P/E is 57.4 for CAI and 138.8 for MRK. Dividend yield: CAI none, MRK 2.47%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CAI$5.5B
MRK$341B
MRK is 62 times CAI
Revenue, 12 months
CAI$1.0B
MRK$67.4B
MRK is 64 times CAI
Net income, 12 months
CAI$96M
MRK$2.5B
MRK is 26 times CAI
Operating margin
CAI13.4%
MRK–
ROIC
CAI11.5%
MRK3.9%
7.6 points apart
P/E
CAI57.4
MRK138.8
MRK is 2.4 times CAI
Dividend yield
CAI0.0%
MRK2.5%
2.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CAI-17.8%
MRK+52.7%
| Period | CAIWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -17.8%Price -17.8% | +52.7%Price +48.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CAICaris Life SciencesMRKMerck & Company
| Price | $19.50 | $137.75 |
|---|---|---|
| Market value | $5.5B | $341B |
| Enterprise value (EV) | – | $385B |
| P/E | 57.4 | 138.8 |
| P/E, 5-year median | – | 14.8 |
| P/B | 8.6 | 7.6 |
| EV/EBIT | – | 80.8 |
| Free cash flow yield | 0.5% | 4.3% |
| Revenue, 12 months | $1.0B | $67.4B |
|---|---|---|
| Net income, 12 months | $96M | $2.5B |
| Free cash flow, 12 months | $29M | $14.7B |
| Earnings per share, 12 months | $0.34 | $0.98 |
| Revenue growth, year on year | 97.0% | 1.3% |
| Revenue growth a year, past | +62.9%over 2 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | 13.4% | – |
| Net margin | 9.2% | 3.6% |
| ROIC | 11.5% | 3.9% |
| ROE | 16.7% | 5.2% |
| Cash | – | $9.7B |
|---|---|---|
| Total debt | – | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | 3.3× | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | 0.0% | 1.5% |
| Shareholder yield | – | 4.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($341B) is about 61.8 times Caris Life Sciences ($5.5B), at today's prices.
Since November 17, 2025, CAI's price moved -17.8% and MRK's +48.3%. With dividends: CAI -17.8% (-17.8% a year), MRK +52.7% (+52.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Caris Life Sciences and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 57.4 for CAI and 138.8 for MRK. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 9.2% for Caris Life Sciences and 3.6% for Merck & Company, and the operating margin 13.4% and –. Revenue was $1.0B and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.